Recurrent endometrial carcinoma

1 paper

Human trial1

Trial sponsors

National Cancer Institute
2 trialsPhase 33,713 people
M.D. Anderson Cancer Center
1 trialPhase 290 people
Jonsson Comprehensive Cancer Center
1 trialPhase 250 people
Mayo Clinic
1 trialPhase 134 people
Case Comprehensive Cancer Center
1 trialPhase 112 people
Floor Backes, MD
1 trialEarly phase 12 people

Latest

Journal of Clinical Oncology26 Jan

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

Non-randomised trial in 38 peoplemTOR inhibitors